Outcome analysis for stage IE and IIE thyroid lymphoma.

Area of Science:

• Oncology
• Radiotherapy
• Hematology

Background:

• Thyroid lymphoma management historically showed modest results with radiotherapy alone.
• Non-Hodgkin's lymphoma of the thyroid gland presents unique challenges in treatment and prognosis.

Purpose of the Study:

• To evaluate the outcomes of thyroid lymphoma patients treated with radiotherapy alone versus combined modality therapy (chemotherapy and radiotherapy).
• To identify prognostic factors influencing local-regional tumor control, disease-free survival (DFS), and overall survival (OS).

Main Methods:

• Retrospective analysis of 27 patients with stages IE and IIE non-Hodgkin's lymphoma of the thyroid gland treated between 1960 and 1998.
• Patients received either radiotherapy alone or combined modality therapy (chemotherapy followed by radiotherapy).
• Kaplan-Meier method for survival analysis and Cox regression for prognostic factor evaluation.

Main Results:

• A crude local tumor control rate of 85% was observed, with no significant factor identified for local control.
• The 5-year disease-free survival (DFS) and overall survival (OS) for the entire cohort were 57% and 56%, respectively.
• Age (<65 vs. >65 years) and clinical stage (I vs. II) were significant predictors of DFS. Age and local tumor control were significant predictors of OS in multivariate analysis.

Conclusions:

• Primary thyroid gland lymphomas have a favorable prognosis with appropriate therapy.
• Prognosis is significantly influenced by patient age at presentation and clinical stage.
• Combined modality therapy (chemotherapy with radiotherapy) is warranted for intermediate- and high-grade thyroid lymphoma due to risks of local-regional and distant failure.